EBOS GROUP LIMITED (EBO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBO

EBO - EBOS GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 3.4
Index: ASX300 | ALL-ORDS

EBOS Group distributes healthcare, pharmaceutical and animal-care products and provides related services across Australasia.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$18.57

24 Aug
2026

-0.390

OPEN

$19.05

-2.06%

HIGH

$19.16

93,363

LOW

$18.49

TARGET
$23.81 28.2% upside
Franking for last dividend paid out: 97%
OTHER COMPANIES IN THE SAME SECTOR
ACL . ALC . BMT . DOC . HLS . IDX . M7T . MPL . MVF . NHF . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
EBO: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 109.8 121.8 xxx
DPS (cps) xxx 104.5 102.0 xxx
EPS Growth xxx 0.1% 10.9% xxx
DPS Growth xxx - 7.4% - 2.4% xxx
PE Ratio xxx N/A 15.4 xxx
Dividend Yield xxx N/A 5.4% xxx
Div Pay Ratio(%) xxx 95.2% 83.8% xxx

Dividend yield today if purchased 3 years ago: 3.16%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 5.58

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 05/03 - ex-div 42.69c (franking 95%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx109.8
DPS All xxxxxxxxxxxxxxx104.5
Sales/Revenue xxxxxxxxxxxxxxx13,486.7 M
Book Value Per Share xxxxxxxxxxxxxxx1,328.0
Net Operating Cash Flow xxxxxxxxxxxxxxx348.9 M
Net Profit Margin xxxxxxxxxxxxxxx1.67 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx8.21 %
Return on Invested Capital xxxxxxxxxxxxxxx5.13 %
Return on Assets xxxxxxxxxxxxxxx2.98 %
Return on Equity xxxxxxxxxxxxxxx8.21 %
Return on Total Capital xxxxxxxxxxxxxxx8.45 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx89.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx151 M
Long Term Debt xxxxxxxxxxxxxxx1,744 M
Total Debt xxxxxxxxxxxxxxx1,896 M
Goodwill - Gross xxxxxxxxxxxxxxx2,269 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx239 M
Price To Book Value xxxxxxxxxxxxxxx1.29

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx146.3 M
Capex % of Sales xxxxxxxxxxxxxxx1.08 %
Cost of Goods Sold xxxxxxxxxxxxxxx12,530 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx578 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx139 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

20/08/2026

1

Buy

$22.50

21.16%

Following Ebos Group's FY26 results, Citi maintains its Buy rating but lowers its target by -$2.00 to $22.50.

First Take: EBOS Group's FY26 result was in line with Citi's expectations across the P&L, with revenue of $13.5bn and core EBITDA of $614m, up 10% and 5%, respectively.

Healthcare revenue rose 9% to $12.6bn, while Animal Care revenue increased 35% to $907m, with operational execution tracking plans outlined at the recent strategy day.

FY27 core EBITDA guidance of $635m-$655m brackets consensus, with the midpoint implying around 5% growth, while Citi sits at the top end of the range.

The broker believes guidance could prove conservative as the completed distribution centre network drives benefits over the next 2-3 years.

UBS

xx/xx/xxxx

1

xxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

24/08/2026

2

Overweight

-

-

Jarden maintains its Overweight recommendation for Ebos Group with its target price reduced to NZ$29.40 from NZ$30.50 following an FY26 result marked by underlying EBITDA growth of 5% to $614m in line with expectations at both level and mix.

Initial FY27 underlying EBITDA guidance of 5% growth at the midpoint met expectations while accounting for fuel and foreign exchange headwinds.

The broker's estimates incorporate nominal changes to near-term operating numbers alongside allowances for ongoing bolt-on acquisitions.

Higher long-term capital expenditure is factored into projections to support an underlying EBITDA growth profile of approximately 5% annually and maintain a return on capital employed around 15%.

The analyst views the result as signalling the closure of a difficult reset period and marking a return to compounding mid-single digit growth.

FORECAST
Jarden forecasts a full year FY27 dividend of 102.00 cents and EPS of 148.00 cents.
Jarden forecasts a full year FY28 dividend of 108.00 cents and EPS of 158.00 cents.
Access Extra Coverage Research History >

EBO STOCK CHART

FNArena News on EBO

1
Australian Broker Call *Extra* Edition – Aug 24, 2026

Aug 24 2026 - Daily Market Reports
2
FNArena Corporate Results Monitor – 20-08-2026

Aug 20 2026 - Australia
3
Australian Broker Call *Extra* Edition – Aug 17, 2026

Aug 17 2026 - Daily Market Reports
4
Treasure Chest: Beware Aussie Healthcare

Jul 17 2026 - Treasure Chest
5
Rudi’s View: Small Cap Favourites, AI & More

Jul 16 2026 - Rudi's View

Latest Healthcare services News

1
Treasure Chest: Beware Aussie Healthcare

Jul 17 2026 - Treasure Chest
2
Major UK Win Highlights Alcidion’s Potential

May 27 2026 - Small Caps
3
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
4
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
5
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
6
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
7
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
8
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
9
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
10
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps